Medicare Part D Pharmacy Steering in 2026: What It Costs When Your Plan's PBM Sends You to Its Own Pharmacy Instead of the Cheapest One
The question nobody asks at the pharmacy counter
You drop off a prescription. The pharmacist tells you the copay. You pay it and leave. Most people never ask: is this the price my plan negotiated, or just the price this particular pharmacy is charging me today?
That question matters more than it used to. A recent KFF Health News investigation, "The Market Forces Quietly Adding Thousands to Patient Bills," documented a specific mechanism: insurers that own their own pharmacy benefit manager (PBM) and their own retail or mail-order pharmacy can steer you toward that in-house pharmacy — and if it doesn't stock your drug, or doesn't offer it at the lowest contracted price, you're the one who absorbs the difference. This isn't a rare edge case. It's baked into how most large Part D plans and Medicare Advantage prescription drug plans (MA-PDs) are structured in 2026, because the same handful of companies (CVS Caremark/Aetna, Optum Rx/UnitedHealthcare, Express Scripts/Cigna) run the PBM, the insurer, and the pharmacy.
This post walks through the actual dollar math — using Toravine's analysis of the cms_medicare_plan_premiums, medigap_rates, and cms_medicare_irmaa datasets alongside the reporting above — so you can figure out whether your specific plan, your specific pharmacy, and your specific drug list put you at risk of this markup.
The mechanism: same drug, two prices, one pharmacy that "just happens" to be more convenient
Here's how it works in practice. Your Part D or MA-PD plan has a preferred pharmacy network. In many of the largest plans, the lowest copay tier is only available at a pharmacy owned by — or closely affiliated with — the same parent company as your PBM. If your local independent pharmacy or a non-preferred chain fills the same prescription, you pay a higher cost-sharing tier, sometimes double or triple the preferred rate.
The twist the KFF reporting flags: sometimes the preferred, in-house pharmacy simply doesn't stock the drug you were prescribed, or only stocks a specific package size or brand formulation. When that happens, you're not choosing between "cheap in-network" and "expensive out-of-network" — you're forced out-of-network by your own plan's supply gap, and you pay the non-preferred price for a drug you never had a real choice about.
Worked example: a maintenance drug across three pharmacy scenarios
Take a common Part D scenario — a 30-day supply of a brand-name blood thinner like a factor Xa inhibitor, a Tier 3 preferred brand drug in most 2026 formularies.
| Fill scenario | Cost-sharing tier applied | Your cost for 30-day supply | Annual cost (12 fills) |
|---|---|---|---|
| Insurer-owned preferred pharmacy, drug in stock | Preferred brand copay | $47 | $564 |
| Insurer-owned pharmacy, drug NOT stocked → forced to outside pharmacy | Non-preferred brand copay | $115 | $1,380 |
| Independent pharmacy, no preferred network relationship | Standard/non-preferred cash-adjacent rate | $187 | $2,244 |
That's a $1,680 annual swing between the best-case and worst-case fill path for the exact same medication, same plan, same person — the only variable is which pharmacy actually had the drug on the shelf the day you needed it. This is the kind of analysis Toravine runs for you — so you don't have to call three pharmacies and compare receipts yourself before every refill.
This dynamic compounds with the formulary tier-placement risk we've written about before: if you're also dealing with a drug that got bumped from Tier 2 to Tier 3 mid-year, the pharmacy-steering markup stacks on top of the tier markup. See our breakdown in Part D Formulary Tier Placement in 2026 for how the same drug can cost $45 or $470 depending on tier alone — before you even factor in which pharmacy fills it.
Why this got worse, not better, heading into 2027
The second piece of this story is about incentives at the plan level, and it's why 2026 is the year to check your specific situation rather than assume the plan that worked in 2025 still works.
Healthcare Dive reported that CMS's draft 2027 star ratings cutpoints are harder to hit — roughly half of the measurement thresholds moved up, meaning plans need to perform better just to hold the same star rating they had before. Star ratings drive quality bonus payments, and quality bonus payments are a major funding source for the supplemental benefits and low-copay drug tiers that make MA-PD plans attractive in the first place.
When a plan's bonus dollars shrink because it fell below a harder 2027 cutpoint, insurers have a limited number of levers to pull to protect margin: raise premiums, narrow the pharmacy network further (pushing more members toward the cheapest-for-the-insurer owned pharmacy), or tighten the formulary. We covered the mechanics of this rebate math in Medicare Advantage Star Rating Drop From 4 to 3.5 Stars — the short version is that a half-star drop can mean millions in lost rebate dollars for an insurer, and those dollars have to come from somewhere in your plan design.
Combine that with the vertical-integration dynamic above, and the practical takeaway is this: the plans most likely to tighten pharmacy networks in 2027 are the same plans facing the hardest star-rating math — which, per CMS's own draft data, is roughly half of all rated contracts. If your MA-PD plan is one of them, your preferred-pharmacy list and your formulary are both candidates for change at the next Annual Enrollment Period. We go deeper on what the broader 2027 rule means for premiums and formularies in CMS 2027 Final Part C and D Rule.
How much this varies by where you live
This isn't evenly distributed. Toravine's analysis of the census_acs_medicare dataset (6,287 rows covering Medicare-age population by geography) shows that rural counties and small metro areas have far fewer pharmacy options within a reasonable driving distance — often just the chain drugstore and maybe one independent. When the chain drugstore also happens to be the PBM-owned "preferred" pharmacy, rural beneficiaries have essentially no negotiating leverage: there's no cheaper in-network alternative to drive to. Urban and dense-suburban beneficiaries, by contrast, typically have three or more preferred-network options within a few miles, which gives real price-shopping room even within the same plan's network rules.
The practical implication: if you live somewhere with limited pharmacy density, the pharmacy-steering risk described above isn't a minor annoyance — it's close to a fixed cost, because you may not have a second preferred pharmacy to route around a stock-out. That's a reason to weigh formulary and pharmacy network access more heavily than premium alone when comparing plans, something Toravine factors in when you model your specific ZIP code and drug list.
Who catches these bills before they compound
There's a human piece to this too. A KFF Health News column, "When a Friend Becomes a Caregiver," documents how often it's not an adult child but a friend or neighbor who ends up managing an older adult's day-to-day logistics — including, in many cases, noticing that a pharmacy bill jumped or that a refill got denied. If you're managing this for yourself, build the habit of checking the receipt total against last month's, not just the copay category. If you're the friend or informal caregiver, a jump from $47 to $187 on a routine refill is exactly the kind of thing that's easy to miss unless someone is specifically looking for it — and exactly the kind of thing that adds up to real money by December.
The comparison table you should actually run
Before your next refill, or before Open Enrollment, pull together these four numbers for each maintenance drug you take:
| What to check | Where to find it | Why it matters |
|---|---|---|
| Preferred pharmacy copay for this drug, this tier | Your plan's Evidence of Coverage / formulary document | Baseline "best case" price |
| Whether your preferred pharmacy currently stocks this exact drug/dose | Call the pharmacy directly, don't assume | Stock-outs force non-preferred pricing |
| Non-preferred/standard cost-sharing for the same drug | Same formulary document, different column | Your "worst case if stock-out happens" number |
| Cash price at 1-2 independent pharmacies nearby | GoodRx or a direct call | Sometimes cheaper than non-preferred insurance pricing entirely |
Running these four checks across even 2-3 maintenance medications is the kind of spreadsheet work most people never get around to doing manually. You can model this for your specific drug list and ZIP code at Toravine, rather than calling five pharmacies yourself every time a refill comes up short.
What to actually do about it
- Ask your pharmacy directly whether they're the plan's preferred pharmacy for your specific drug and dose — not just "in-network," which is a lower bar.
- Call ahead of a refill if you've had a stock-out before. A five-minute call can save a $100+ surprise at pickup.
- Re-run your formulary comparison every Open Enrollment, not just when something goes wrong. Formularies and preferred-pharmacy lists both reset annually, and a plan that had your drug at Tier 2 with a stocked preferred pharmacy this year can quietly change either variable for next year.
- Weigh pharmacy access alongside premium when you compare plans — a $0-premium MA-PD with a thin preferred-pharmacy network in a rural area can cost more out-of-pocket over a year than a plan with a modest premium and broader pharmacy access, especially for specialty or brand-name maintenance drugs. Our formulary tier-change breakdown in Part D Tier 2 to Tier 3 Formulary Change walks through a parallel version of this math for prior-authorization denials.
The plan that fit your prescriptions and your pharmacy access in January can look different by October — different star rating, different rebate dollars, different preferred pharmacy list. The only way to know if you're on the losing end of that shift is to re-check the numbers with your actual drugs and your actual ZIP code before you re-enroll. That's exactly the comparison Toravine is built to run.
Sources
- Half of Medicare Advantage stars thresholds harder to reach in 2027 — Healthcare Dive
- When a Friend Becomes a Caregiver — KFF Medicare
- The Market Forces Quietly Adding Thousands to Patient Bills — KFF Medicare
- Health Catalyst appoints new CEO — Healthcare Dive
- Veterans Affairs taps Amwell for telehealth revamp — Healthcare Dive